Posted by Michael Wonder on 15 Jul 2020
The impact of managed entry agreements on pharmaceutical prices
6 July 2020 - Managed entry agreements have been used for several years, with the aim of curbing the growth of pharmaceutical expenditure and enhancing patient access to innovation.
Yet, much remains to be understood about their economic implications.
This paper studies the impact of managed entry agreements on list prices, that is, prices before the deduction of any discount.
